US · Healthcare · Biotechnology
EPS came in at -0.84 against a street estimate of -0.90 — a beat of 6.7%.
Analysts rate MoonLake Immunotherapeutics a strong buy (16 buy, 0 hold, 0 sell out of 16) with an average price target of $28.54.
| Fund | Stake |
|---|---|
| Bvf Inc | 18.80% |
| Deep Track Capital, LP | 8.22% |
| Cormorant Asset Management, LLC | 5.26% |
| HHG PLC | 4.06% |
| D. E. Shaw & Co LP | 3.95% |
| Logos Global Management LP | 3.14% |
| Weiss Asset Management LP | 2.01% |
| MPM Oncology Impact Management LP | 1.89% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 MOONLAKE IMMUNOTHERAPEUTICS - Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Cash position: $477.9 million in cash and cash equivalents plus $59.1 million | 2026-08-10 |
| Results announced · Q3 2026 MOONLAKE IMMUNOTHERAPEUTICS - INVESTOR SUMMARY HEADLINE NUMBERS • Cash Position: $537.0 million in cash, cash equivalents and short-term marketable | 2026-08-10 |
| Company announcement · Q3 2026 MOONLAKE IMMUNOTHERAPEUTICS - FORM 8-K SUMMARY HEADLINE NUMBERS • Company completed exercise of underwriter option to purchase 1,500,000 additional | 2026-07-15 |
| Material agreement · Q2 2026 MOONLAKE IMMUNOTHERAPEUTICS - FORM 8-K SUMMARY HEADLINE NUMBERS • Company conducting public offering of 9,000,000 Class A ordinary shares at $20.00 | 2026-06-25 |
| Reg FD disclosure · Q2 2026 MOONLAKE IMMUNOTHERAPEUTICS - FORM 8-K SUMMARY HEADLINE NUMBERS • Company announced Week 52 results from Phase 3 VELA clinical trials (VELA-1 and VE | 2026-06-22 |
| Quarterly report · Q1 2026 MOONLAKE IMMUNOTHERAPEUTICS - Q1 2026 SUMMARY HEADLINE NUMBERS • Cash Position: $298.5 million in cash and cash equivalents as of March 31, 2026 (do | 2026-05-11 |
| Proxy statement · Q2 2026 MOONLAKE IMMUNOTHERAPEUTICS — PROXY SUMMARY --- CEO COMPENSATION & CHANGE • Dr. Jorge Santos da Silva (CEO): Total 2025 compensation: $2,024,167 | 2026-04-21 |
| Annual report FY2025 MOONLAKE IMMUNOTHERAPEUTICS – 10-K SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Market capitalization (as of June 30, 2025): Approximately $1.34 | 2026-02-25 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for MoonLake Immunotherapeutics — free to start.
Google PlayApp StoreData updated 2026-09-18.